American Statistical Association
I will discuss the use of cancer recurrences to estimate the treatment effect in phase III clinical trials. The first part will focus on the validation of progression-free survival as a surrogate endpoint for overall survival in lung cancer in a meta-analysis setting. Progression-free survival is shown to be a valid surrogate in both chemotherapy and radiotherapy trials, emphasizing the interest of those intermediate events. In a second part, I will discuss the use of individual predictions from a joint model in clinical trial setting. Recurrences are used to predict and impute the time of death for censored patients, increasing the number of events in the analysis. Two imputation methods are compared, and their performances are compared to the analysis based on observed events only. Methods are applied to a trial of chemotherapy in breast cancer.
|Date:||Wednesday, January 25, 2017|
|Time:||4:00 - 5:00 P.M.|
Memorial Sloan Kettering Cancer Center
Department of Epidemiology and Biostatistics
485 Lexington Avenue
(Between 46th & 47th Streets)
2nd Floor, Conference Room B
New York, New York
**Outside visitors please email email@example.com for building access.
You must be on the security list to enter the floor.